
    
      Patients who presenting with an indication for cholangioscopy or presenting with a possible
      indication for cholangioscopy to be determined during the ERCP procedure immediately
      preceding the SpyGlass procedure will join this study, totally 500 patients across 16 sites
      throughout China will participate in study. After SpyGlass operation, all patients will be
      followed for 72 hours to observe adverse events, and patients with indeterminate stricture or
      undefined filling defect indication with tissue sampling not yielding histopathology positive
      for malignancy and unresolved device and/or procedure related SAE at 72 Hours will continue
      to be followed up until 6 months. Finally, procedure success rate will be analyzed as primary
      endpoint, and SAEs and impact of patients management will be analyzed as secondary endpoint.
    
  